Home » Stocks » KALA

Kala Pharmaceuticals, Inc. (KALA)

Stock Price: $5.01 USD -0.46 (-8.41%)
Updated May 13, 2021 2:24 PM EDT - Market open
Market Cap 344.54M
Revenue (ttm) 8.56M
Net Income (ttm) -112.78M
Shares Out 61.66M
EPS (ttm) -1.96
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $5.01
Previous Close $5.47
Change ($) -0.46
Change (%) -8.41%
Day's Open 5.43
Day's Range 4.90 - 5.53
Day's Volume 2,738,081
52-Week Range 4.90 - 14.68

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases ...

1 week ago - Business Wire

Kala Pharma (KALA) delivered earnings and revenue surprises of 3.92% and -10.28%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

Shares of Kala Pharmaceuticals (NASDAQ:KALA) fell 0.5% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 9.26% over the past year to ($0.49), wh...

1 week ago - Benzinga

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases ...

1 week ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases ...

2 weeks ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Compan...

1 month ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases ...

1 month ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases ...

2 months ago - Business Wire

Kala Pharma (KALA) delivered earnings and revenue surprises of -19.57% and -6.44%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases ...

2 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases ...

2 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Compan...

2 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases...

2 months ago - Business Wire

Kala Pharma (KALA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Compan...

3 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases...

4 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases ...

4 months ago - Business Wire

Kala Pharmaceuticals Should Have Limited Downside With Eysuvis Now Approved

4 months ago - Seeking Alpha

The Play On Kala Pharmaceuticals

4 months ago - Seeking Alpha

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Compan...

5 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases...

5 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases ...

6 months ago - Business Wire

Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Kala Pharma (KALA) delivered earnings and revenue surprises of -13.64% and 9.74%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases ...

6 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases ...

6 months ago - Business Wire

Good news from the FDA translated to bad news for Kala's share price.

6 months ago - The Motley Fool

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases ...

6 months ago - Business Wire

Investors need to pay close attention to Kala Pharmaceuticals (KALA) stock based on the movements in the options market lately.

7 months ago - Zacks Investment Research

Kala Pharmaceuticals (KALA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

7 months ago - Zacks Investment Research

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc.

8 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc.

8 months ago - Business Wire

Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

Kala Pharma (KALA) delivered earnings and revenue surprises of 0.00% and 9.89%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc.

9 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc.

9 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc.

9 months ago - Business Wire

Kala Pharma (KALA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

Is (KALA) Outperforming Other Medical Stocks This Year?

11 months ago - Zacks Investment Research

Top Ranked Momentum Stocks to Buy for May 26th

Other stocks mentioned: KOPN, NERV, RYAM
11 months ago - Zacks Investment Research

Is (KALA) Outperforming Other Medical Stocks This Year?

11 months ago - Zacks Investment Research

Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Kala Pharma (KALA) delivered earnings and revenue surprises of -5.88% and -57.02%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Shares of Kala Pharmaceuticals (NASDAQ:KALA) were flat in pre-market trading after the company reported Q1 results.

1 year ago - Benzinga

Does Kala Pharmaceuticals (KALA) have what it takes to be a top stock pick for momentum investors? Let's find out.

1 year ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor in Kala Pharmaceuticals.

1 year ago - Zacks Investment Research

Does Kala Pharmaceuticals (KALA) have what it takes to be a top stock pick for momentum investors? Let's find out.

1 year ago - Zacks Investment Research

Coronavirus shows signs of slowdown in the United States and some other countries. While investors look for positive developments in the stock market, here are five must-buy stocks poised to grow.

Other stocks mentioned: DHT, FRO, SMED, SMMT
1 year ago - Zacks Investment Research

Picking breakout stocks is one of the most favored methods for those utilizing an active investing approach since this strategy offers the promise of superlative returns.

Other stocks mentioned: CCOEY, UNICY
1 year ago - Zacks Investment Research

Kala Pharmaceuticals Looks To Keep Rally Going

1 year ago - Seeking Alpha

About KALA

Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's product candidates include EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development programs co... [Read more...]

Industry
Biotechnology
IPO Date
Jul 20, 2017
CEO
Mark Iwicki
Employees
188
Stock Exchange
NASDAQ
Ticker Symbol
KALA
Full Company Profile

Financial Performance

In 2020, KALA's revenue was $6.36 million, an increase of 4.74% compared to the previous year's $6.07 million. Losses were -$104.33 million, 10.6% more than in 2019.

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for KALA stock is "Buy." The 12-month stock price forecast is 20.33, which is an increase of 305.79% from the latest price.

Price Target
$20.33
(305.79% upside)
Analyst Consensus: Buy